Skip to content
Evigrade
CriticalClass Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

Ranolazine blocks the IKr potassium current and prolongs the heart-rate-corrected QT interval (QTc) in a concentration-dependent way (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Quinidine is a class IA antiarrhythmic that also prolongs the QT interval in a dose-related way. This may lead to polymorphic ventricular tachycardia, including torsade de pointes (quinidine label, US Food and Drug Administration, FDA). At therapeutic levels, quinidine inhibits CYP2D6 and effectively turns extensive metabolisers into poor metabolisers (FDA). CYP2D6 also partly metabolises ranolazine (EMA). With ranolazine 1000 mg twice daily, the strong CYP2D6 inhibitor paroxetine raised ranolazine levels 1.2-fold on average, which needs no dose adjustment. With 500 mg twice daily, a strong CYP2D6 inhibitor could increase the area under the concentration curve (AUC) of ranolazine by about 62% (ranolazine SmPC, EMA). CYP3A4 is the main route of quinidine elimination, and ranolazine weakly inhibits this enzyme. The documents give no figures on how ranolazine changes quinidine levels (quinidine FDA label and ranolazine SmPC, EMA).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Torsade de pointes is life-threatening (quinidine label, US Food and Drug Administration, FDA). With quinidine, the risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium and high quinidine levels, but it may appear without these factors (quinidine FDA label). Other ventricular arrhythmias with quinidine include frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation (quinidine FDA label). The higher the ranolazine level, the more likely dose-related adverse reactions such as nausea and dizziness become (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Warning signs of a possible arrhythmia are feeling faint or lightheaded and an irregular or fast heartbeat (ranolazine FDA label).

Management

The combination is contraindicated. The European ranolazine summary of product characteristics (SmPC) contraindicates ranolazine with class Ia and class III antiarrhythmics other than amiodarone and names quinidine (ranolazine SmPC, European Medicines Agency, EMA). Quinidine is not in the Spanish medicines register (CIMA), which lists only hydroquinidine, a different substance. The US quinidine label does not mention ranolazine but requires caution whenever quinidine is prescribed with drugs that CYP2D6 metabolises (quinidine label, US Food and Drug Administration, FDA). The US ranolazine label is milder than the European SmPC: it has no contraindication and only notes little experience with other QT-prolonging drugs (ranolazine FDA label). Use ranolazine with caution in congenital or familial long QT syndrome, known acquired QT prolongation and with other drugs that affect the QT interval (ranolazine SmPC, EMA). During quinidine treatment, the heart-rate-corrected QT interval (QTc) on the electrocardiogram (ECG) appears to be the best predictor of arrhythmia. Reduce the total daily dose if QRS widens to 130% of baseline, QTc lengthens to 130% of baseline and exceeds 500 ms, P waves disappear, or significant tachycardia, symptomatic bradycardia or hypotension develops (quinidine FDA label). In people with heart disease or other risk factors, the label generally advises starting quinidine and changing its dose where continuous monitoring and resuscitation are available (quinidine FDA label). In unstable polymorphic ventricular tachycardia, including torsade de pointes, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and, if possible, correct them promptly (quinidine FDA label, overdosage section).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Quinidine

Other interactions with Ranolazine